Literature DB >> 25471794

Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice.

Stefano Menini1, Carla Iacobini, Carlo Ricci, Claudia Blasetti Fantauzzi, Giuseppe Pugliese.   

Abstract

AIMS/HYPOTHESIS: AGEs are involved in diabetic complications and might be responsible for the phenomenon of 'hyperglycaemic memory'. D-Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe-null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection.
METHODS: Apoe-null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic Apoe-null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR.
RESULTS: DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice. CONCLUSIONS/
INTERPRETATION: These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25471794     DOI: 10.1007/s00125-014-3467-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  36 in total

1.  A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified.

Authors:  L Brånén; L Pettersson; M Lindholm; S Zaina
Journal:  Histochem J       Date:  2001-04

Review 2.  Clinical review: The role of advanced glycation end products in progression and complications of diabetes.

Authors:  Su-Yen Goh; Mark E Cooper
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

3.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Authors:  A C Li; K K Brown; M J Silvestre; T M Willson; W Palinski; C K Glass
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 4.  A re-evaluation of the antioxidant activity of purified carnosine.

Authors:  E A Decker; S A Livisay; S Zhou
Journal:  Biochemistry (Mosc)       Date:  2000-07       Impact factor: 2.487

5.  Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives.

Authors:  Giancarlo Aldini; Roberto Maffei Facino; Giangiacomo Beretta; Marina Carini
Journal:  Biofactors       Date:  2005       Impact factor: 6.113

6.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

Authors:  M Shichiri; H Kishikawa; Y Ohkubo; N Wake
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

Review 7.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

Review 8.  Reactive carbonyls and oxidative stress: potential for therapeutic intervention.

Authors:  Elizabeth M Ellis
Journal:  Pharmacol Ther       Date:  2007-05-08       Impact factor: 12.310

9.  Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.

Authors:  Sih Min Tan; Arpeeta Sharma; Nada Stefanovic; Derek Y C Yuen; Tom C Karagiannis; Colin Meyer; Keith W Ward; Mark E Cooper; Judy B de Haan
Journal:  Diabetes       Date:  2014-04-16       Impact factor: 9.461

Review 10.  Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.

Authors:  A Negre-Salvayre; C Coatrieux; C Ingueneau; R Salvayre
Journal:  Br J Pharmacol       Date:  2007-07-23       Impact factor: 8.739

View more
  23 in total

Review 1.  AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.

Authors:  Kailash Prasad
Journal:  Mol Cell Biochem       Date:  2019-05-11       Impact factor: 3.396

2.  Catalpol ameliorates diabetic atherosclerosis in diabetic rabbits.

Authors:  Jiang-Yue Liu; Chen-Zhao Zheng; Xin-Ping Hao; Dai-Juan Zhang; An-Wei Mao; Ping Yuan
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

3.  Reactive Carbonyl Species Scavengers-Novel Therapeutic Approaches for Chronic Diseases.

Authors:  Sean S Davies; Linda S Zhang
Journal:  Curr Pharmacol Rep       Date:  2017-02-14

4.  FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice.

Authors:  Carla Iacobini; Stefano Menini; Claudia Blasetti Fantauzzi; Carlo M Pesce; Andrea Giaccari; Enrica Salomone; Annunziata Lapolla; Marica Orioli; Giancarlo Aldini; Giuseppe Pugliese
Journal:  Br J Pharmacol       Date:  2017-12-08       Impact factor: 8.739

5.  Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High-Fat Diet: Possible Role of the NLRP3 Inflammasome.

Authors:  Claudia Blasetti Fantauzzi; Stefano Menini; Carla Iacobini; Chiara Rossi; Eleonora Santini; Anna Solini; Giuseppe Pugliese
Journal:  Oxid Med Cell Longev       Date:  2017-11-15       Impact factor: 6.543

Review 6.  On the Relationship between Energy Metabolism, Proteostasis, Aging and Parkinson's Disease: Possible Causative Role of Methylglyoxal and Alleviative Potential of Carnosine.

Authors:  Alan R Hipkiss
Journal:  Aging Dis       Date:  2017-05-02       Impact factor: 6.745

7.  Carnosine Attenuates the Development of both Type 2 Diabetes and Diabetic Nephropathy in BTBR ob/ob Mice.

Authors:  Thomas Albrecht; Maaike Schilperoort; Shiqi Zhang; Jana D Braun; Jiedong Qiu; Angelica Rodriguez; Diego O Pastene; Bernhard K Krämer; Hannes Köppel; Hans Baelde; Emile de Heer; Alessandra Anna Altomare; Luca Regazzoni; Alessandra Denisi; Giancarlo Aldini; Jacob van den Born; Benito A Yard; Sibylle J Hauske
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

8.  Oral anserine supplementation does not attenuate type-2 diabetes or diabetic nephropathy in BTBR ob/ob mice.

Authors:  Inge Everaert; Thibaux Van der Stede; Jan Stautemas; Maxime Hanssens; Cleo van Aanhold; Hans Baelde; Lynn Vanhaecke; Wim Derave
Journal:  Amino Acids       Date:  2021-07-15       Impact factor: 3.520

9.  The protective effects of oral low-dose quercetin on diabetic nephropathy in hypercholesterolemic mice.

Authors:  Isabele B S Gomes; Marcella L Porto; Maria C L F S Santos; Bianca P Campagnaro; Agata L Gava; Silvana S Meyrelles; Thiago M C Pereira; Elisardo C Vasquez
Journal:  Front Physiol       Date:  2015-09-02       Impact factor: 4.566

Review 10.  Cellular and Molecular Mechanisms of Diabetic Atherosclerosis: Herbal Medicines as a Potential Therapeutic Approach.

Authors:  Jinfan Tian; Yanfei Liu; Yue Liu; Keji Chen; Shuzheng Lyu
Journal:  Oxid Med Cell Longev       Date:  2017-08-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.